Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
GRI Bio Announces FDA Clearance Of IND For Lead Program GRI-0621, A Type 1 Invariant NKT Antagonist For The Treatment Of Idiopathic Pulmonary Fibrosis
Clinical development plan leveraging 505(b)(2) regulatory pathwayInitiation of Phase 2a biomarker study on track to start before year endCurrently available treatments for IPF are limited to only two approved drugs that
